Low-molecular-weight heparin to prevent postpartum venous thromboembolism

Summary

The risk of venous thromboembolism (VTE) is elevated in the postpartum period. Low-molecular-weight heparin (LMWH) reduces the risk of VTE in many settings but is costly, inconvenient and increases bleeding. Randomised controlled trials (RCT) are required to determine if LMWH prophylaxis provides a clinical benefit in high-risk postpartum women. We sought to determine if a placebo-controlled RCT was feasible. We conducted a multi-national, double-blind pilot RCT in “high risk” postpartum women comparing 21 days of prophylactic dose LMWH to identical saline placebo injections. The primary pilot outcome was mean number of recruited women per centre per month. The planned primary outcome for the full trial was symptomatic objectively confirmed VTE or asymptomatic proximal deep-vein thrombosis diagnosed by a screening bilateral leg vein ultrasound at day 21. In six centres, a total of 1,346 potentially eligible women were approached to participate; 968 were ineligible, leaving 378 (31.5%) eligible patients. Of these, only 25 (6.6%) were randomised at a rate of 0.7 per centre per month. The primary reasons for declining participation were to avoid study injections and being too overwhelmed to participate in research. None of the participants had a VTE during follow-up. In conclusion, despite an adequate number of eligible participants, our double-blind RCT design was not feasible due to a very low consent rate. Other experimental approaches may be necessary to generate evidence in this important area of research.

Keywords

Low-molecular-weight heparin - postpartum - randomised controlled trial - thromboprophylaxis - venous thromboembolism

^* PROSPER Investigators are listed in the Appendix.

• References

• 1 Khan KS, Wojdyla D, Say L. et al. WHO analysis of causes of maternal death: a systematic review. Lancet 2006; 367: 1066-1074.
• 2 Gherman RB, Goodwin TM, Leung B. et al. Incidence, clinical characteristics, and timing of objectively diagnosed venous thromboembolism during pregnancy. Obstet Gynecol 1999; 94: 730-734.
• 3 Heit JA, Kobbervig CE, James AH. et al. Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population-based study. Ann Intern Med 2005; 143: 697-706.
• 4 Jacobsen AF, Skjeldestad FE, Sandset PM. Ante- and postnatal risk factors of venous thrombosis: a hospital-based case-control study. J Thromb Haemost 2008; 06: 905-912.
• 5 Pomp ER, Lenselink AM, Rosendaal FR. et al. Pregnancy, the postpartum period and prothrombotic defects: risk of venous thrombosis in the MEGA study. J Thromb Haemost 2008; 06: 632-637.
• 6 Nelson-Piercy C. Hazards of heparin: allergy, heparin-induced thrombocytopenia and osteoporosis. Baillieres Clin Obstet Gynaecol 1997; 11: 489-509.
• 7 Brenner B. Inherited thrombophilia and pregnancy loss. Best Pract Res Clin Haematol 2003; 16: 311-320.
• 8 Lepercq J, Conard J, Borel-Derlon A. et al. Venous thromboembolism during pregnancy: a retrospective study of enoxaparin safety in 624 pregnancies. Br J Obstet Gynecol 2001; 108: 1134-1140.
• 9 Huhle G, Geberth M, Hoffmann U. et al. Management of heparin-associated thrombocytopenia in pregnancy with subcutaneous r-hirudin. Gynecol Obstet Invest 2000; 49: 67-69.
• 10 Greer IA, Nelson-Piercy C. Low-molecular-weight heparins for thrombopro-phylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy. Blood 2005; 106: 401-407.
• 11 Bain E, Wilson A, Tooher R. et al. Prophylaxis for venous thromboembolic disease in pregnancy and the early postnatal period. Cochrane Database Syst Rev 2014; 02: CD001689.
• 12 Gates S, Brocklehurst P, Ayers S. et al. Thromboprophylaxis and pregnancy: two randomized controlled pilot trials that used low-molecular-weight heparin. Am J Obstet Gynecol 2004; 191: 1296-1303.
• 13 Burrows RF, Gan ET, Gallus AS. et al. A randomised double-blind placebo controlled trial of low molecular weight heparin as prophylaxis in preventing venous thrombolic events after caesarean section: a pilot study. Br J Obstet Gyne-col 2001; 108: 835-839.
• 14 Bates SM, Greer IA, Middeldorp S. et al. VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141: e691S-e736S.
• 15 Chan WS, Rey E, Kent NE. et al. Venous thromboembolism and antithrombotic therapy in pregnancy. J Obstet Gynaecol Can 2014; 36: 527-553.
• 16 RCOG. Green-top guideline no. 37: reducing the risk of thrombosis and embolism during pregnancy and the puerperium. 1-10-2009.
• 17 Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihaemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005; 03: 692-694.
• 18 Rodger MA, Hague WM, Kingdom J. et al. Antepartum dalteparin versus no antepartum dalteparin for the prevention of pregnancy complications in pregnant women with thrombophilia (TIPPS): a multinational open-label randomised trial. Lancet. 2014 Epub ahead of print.
• 19 de Vries JIP, van Pampus MG, Hague WM. et al. Low-molecular-weight heparin added to aspirin in the prevention of recurrent early-onset pre-eclampsia in women with inheritable thrombophilia: the FRUIT-RCT. J Thromb Haemost 2012; 10: 64-72.
• 20 Lazo-Langner A, Rodger MA, Barrowman NJ. et al. Comparing multiple competing interventions in the absence of randomized trials using clinical risk-benefit analysis. BMC Med Res Methodol 2012; 12: 3.
• 21 Toerien M, Brookes ST, Metcalfe C. et al. A review of reporting of participant recruitment and retention in RCTs in six major journals. Trials 2009; 10: 52.
• 22 Moher D, Schultz KF, Altman DG. The CONSORT statement: revised recommendation for improving the quality of reports of parallel-group randomised trials. Lancet 2001; 357: 1191-1194.
• 23 Kline CR, Martin DP, Deyo RA. Health consequences of pregnancy and childbirth as perceived by women and clinicians. Obstet Gynecol 1998; 92: 842-848.